{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T20:50:29Z","timestamp":1649105429442},"reference-count":60,"publisher":"FapUNIFESP (SciELO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Bras Endocrinol Metab"],"published-print":{"date-parts":[[2007,4]]},"abstract":"<jats:p>O uso de aspirina \u00e9 recomendado como estrat\u00e9gia de preven\u00e7\u00e3o cardiovascular em pacientes com diabete melito. Em decorr\u00eancia do risco de eventos hemorr\u00e1gicos e da hip\u00f3tese de que poderia haver um agravamento das complica\u00e7\u00f5es microvasculares associado ao uso da aspirina, tem havido importante sub-utiliza\u00e7\u00e3o dessa terapia. Entretanto, est\u00e1 definido que o uso de aspirina n\u00e3o piora a retinopatia diab\u00e9tica e existem evid\u00eancias de que tamb\u00e9m n\u00e3o afeta a fun\u00e7\u00e3o renal em doses usuais (150 mg\/dia). Por outro lado, pacientes com diabete melito parecem necessitar de doses maiores do agente antiplaquet\u00e1rio, o que sugere que esses indiv\u00edduos apresentem a chamada \"resist\u00eancia \u00e0 aspirina\". Os mecanismos dessa resist\u00eancia ainda n\u00e3o est\u00e3o completamente esclarecidos, estando provavelmente relacionados \u00e0 atividade plaquet\u00e1ria intr\u00ednseca anormal. Portanto, o emprego de terap\u00eauticas antiplaquet\u00e1rias alternativas ou a administra\u00e7\u00e3o de doses maiores de aspirina (150-300 mg\/dia) devem ser melhor avaliados em rela\u00e7\u00e3o a um aumento da efic\u00e1cia na preven\u00e7\u00e3o da doen\u00e7a cardiovascular e tamb\u00e9m a poss\u00edveis efeitos nas complica\u00e7\u00f5es microvasculares no diabete melito.<\/jats:p>","DOI":"10.1590\/s0004-27302007000300015","type":"journal-article","created":{"date-parts":[[2007,11,16]],"date-time":"2007-11-16T03:15:54Z","timestamp":1195182954000},"page":"457-465","source":"Crossref","is-referenced-by-count":1,"title":["Aspirina em baixa dosagem em pacientes com diabete melito: riscos e benef\u00edcios em rela\u00e7\u00e3o \u00e0s complica\u00e7\u00f5es macro e microvasculares"],"prefix":"10.1590","volume":"51","author":[{"given":"Eduardo G.","family":"Camargo","sequence":"first","affiliation":[{"name":"Universidade Federal do Rio Grande do Sul"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge Luiz","family":"Gross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Let\u00edcia S.","family":"Weinert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Lavinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra P.","family":"Silveiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes: estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild S","year":"2004","journal-title":"Diabetes Care","ISSN":"http:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1161\/CIRCULATIONAHA.105.548198","article-title":"Revised Adult Treatment Panel III guidelines and cardiovascular disease mortality in men attending a preventive medical clinic","volume":"112","author":"Ardern CI","year":"2005","journal-title":"Circulation","ISSN":"http:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1001\/archinte.162.18.2033","article-title":"The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease","volume":"162","author":"Eidelman RS","year":"2002","journal-title":"Arch Intern Med","ISSN":"http:\/\/id.crossref.org\/issn\/0003-9926","issn-type":"print"},{"key":"ref4","first-page":"1095","article-title":"Increasing global burden of cardiovascular disease: current knowledge and future directions for research on risk factors: special report: the 1997 American Heart Association\u2019s Lewis Atterbury Conner Lecture","volume":"97","author":"Hennekens CH","year":"1998","journal-title":"Circulation","ISSN":"http:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1590\/S0104-42302004000300031","article-title":"Preval\u00eancia de complica\u00e7\u00f5es micro e macrovasculares e seus fatores de risco em pacientes com diabetes melito do tipo 2 em atendimento ambulatorial","volume":"50","author":"Scheffel RS","year":"2004","journal-title":"Rev Assoc Med Bras","ISSN":"http:\/\/id.crossref.org\/issn\/0004-5241","issn-type":"print"},{"key":"ref6","series-title":"USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases","year":"2005"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.2337\/diacare.25.6.1101","article-title":"Risk factors for microalbuminuria and macroalbuminuria in type 2 diabetic patients: A 9-year follow-up study","volume":"25","author":"Murussi M","year":"2002","journal-title":"Diabetes Care","ISSN":"http:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1056-8727(00)00118-5","article-title":"Prognostic factors in Brazilian diabetic patients starting dialysis: a 36-year follow-up study","volume":"14","author":"Bruno RM","year":"2000","journal-title":"J Diabetes Complications","ISSN":"http:\/\/id.crossref.org\/issn\/1056-8727","issn-type":"print"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jdiacomp.2004.12.001","article-title":"Diastolic dysfunction and mortality in diabetic patients on hemodialysis: a 4.25-year controlled prospective study","volume":"19","author":"Zaslavsky LM","year":"2005","journal-title":"J Diabetes Complications","ISSN":"http:\/\/id.crossref.org\/issn\/1056-8727","issn-type":"print"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/archinte.160.8.1093","article-title":"The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus","volume":"160","author":"Valmadrid CT","year":"2000","journal-title":"Arch Intern Med","ISSN":"http:\/\/id.crossref.org\/issn\/0003-9926","issn-type":"print"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s001250050895","article-title":"Heterogeneous nature of microalbuminuria in NIDDM: studies of endothelial function and renal structure","volume":"41","author":"Fioretto P","year":"1998","journal-title":"Diabetologia","ISSN":"http:\/\/id.crossref.org\/issn\/0012-186X","issn-type":"print"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2337\/diabetes.51.4.1157","article-title":"Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes","volume":"51","author":"Stehouwer CDA","year":"2002","journal-title":"Diabetes","ISSN":"http:\/\/id.crossref.org\/issn\/0012-1797","issn-type":"print"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1046\/j.1523-1755.2000.00331.x","article-title":"Inflammation and microalbuminuria in non diabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study","volume":"58","author":"Festa A","year":"2000","journal-title":"Kidney Int","ISSN":"http:\/\/id.crossref.org\/issn\/0085-2538","issn-type":"print"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.2337\/diacare.26.5.1589","article-title":"New insights on oxidative stress and diabetic complications may lead to a causal antioxidant therapy","volume":"26","author":"Ceriello A","year":"2003","journal-title":"Diabetes Care","ISSN":"http:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2337\/diacare.28.suppl_1.S4","article-title":"Standards of medical care in diabetes (Position Statement)","volume":"28","year":"2005","journal-title":"Diabetes Care","ISSN":"http:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2337\/diacare.24.2.197","article-title":"Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey","volume":"24","author":"Rolka DB","year":"2001","journal-title":"Diabetes Care","ISSN":"http:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-115-3-165","article-title":"Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease","volume":"115","author":"Sandler DP","year":"1991","journal-title":"Ann Intern Med","ISSN":"http:\/\/id.crossref.org\/issn\/0003-4819","issn-type":"print"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1096\/fasebj.5.9.1907252","article-title":"Human platelet\/erythroleukemia cell prostaglandin G\/H synthase: cDNA cloning, expression, and gene chromosomal assignment","volume":"15","author":"Funk CD","year":"1991","journal-title":"FASEB J","ISSN":"http:\/\/id.crossref.org\/issn\/0892-6638","issn-type":"print"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"11B","DOI":"10.1016\/0002-9149(91)90379-Y","article-title":"Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for the others agonists","volume":"68","author":"FitzGerald GA","year":"1991","journal-title":"Am J Cardiol","ISSN":"http:\/\/id.crossref.org\/issn\/0002-9149","issn-type":"print"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1096\/fj.03-0645rev","article-title":"Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic","volume":"18","author":"Warner TD","year":"2004","journal-title":"FASEB J","ISSN":"http:\/\/id.crossref.org\/issn\/0892-6638","issn-type":"print"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella-Lawson F","year":"2001","journal-title":"N Engl J Med","ISSN":"http:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono C","year":"2005","journal-title":"N Engl J Med","ISSN":"http:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/hc0302.102609","article-title":"Antioxidative properties of acetylsalicylic acid on vascular tissues from normotensive and hypertensive rats","volume":"105","author":"Wu R","year":"2002","journal-title":"Circulation","ISSN":"http:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1096\/fj.00-0843fje","article-title":"Aspirin inhibits NF-kappaB and protects from angiotensin II-induce organ damage","volume":"15","author":"Muller DN","year":"2001","journal-title":"FASEB J","ISSN":"http:\/\/id.crossref.org\/issn\/0892-6638","issn-type":"print"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7326\/0003-4819-136-2-200201150-00015","article-title":"Aspirin for the primary prevention of cardiovascular events: recommendations and rationale","volume":"136","year":"2002","journal-title":"Ann Intern Med","ISSN":"http:\/\/id.crossref.org\/issn\/0003-4819","issn-type":"print"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","article-title":"Final report on the aspirin component of the ongoing Physicians\u2019 Health Study","volume":"321","year":"1989","journal-title":"N Engl J Med","ISSN":"http:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/bmj.296.6618.313","article-title":"Randomized trial of prophylatic daily aspirin in British male doctors","volume":"296","author":"Peto R","year":"1988","journal-title":"BMJ","ISSN":"http:\/\/id.crossref.org\/issn\/0959-8138","issn-type":"print"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","article-title":"The Medical Research Council\u2019s General Practice Research Framework: Thrombosis Prevention Trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk","volume":"351","year":"1998","journal-title":"Lancet","ISSN":"http:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"for the HOT study group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial","volume":"351","author":"Hanson L","year":"1998","journal-title":"Lancet","ISSN":"http:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0140-6736(00)03539-X","article-title":"Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice","volume":"357","year":"2001","journal-title":"Lancet","ISSN":"http:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.2337\/diacare.26.12.3264","article-title":"Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: Results of the Primary Prevention Project (PPP) trial","volume":"26","author":"Sacco M","year":"2003","journal-title":"Diabetes Care","ISSN":"http:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1001\/archinte.163.17.2006","article-title":"An update on aspirin in the primary prevention of cardiovascular disease","volume":"163","author":"Eidelman RS","year":"2003","journal-title":"Arch Intern Med","ISSN":"http:\/\/id.crossref.org\/issn\/0003-9926","issn-type":"print"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"Ridker PM","year":"2005","journal-title":"N Engl J Med","ISSN":"http:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.295.3.306","article-title":"Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trials","volume":"295","author":"Berger JS","year":"2006","journal-title":"JAMA","ISSN":"http:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients","volume":"324","year":"2002","journal-title":"BMJ","ISSN":"http:\/\/id.crossref.org\/issn\/0959-8138","issn-type":"print"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0002-9149(02)02567-5","article-title":"Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus","volume":"90","author":"Bhatt DL","year":"2002","journal-title":"Am J Cardiol","ISSN":"http:\/\/id.crossref.org\/issn\/0002-9149","issn-type":"print"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt DL","year":"2006","journal-title":"N Engl J Med","ISSN":"http:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0025-6196(12)62658-5","article-title":"Platelet-inhibitor treatment of diabetic nephropathy: a 10-year prospective study","volume":"63","author":"Donadio JV","year":"1988","journal-title":"Mayo Clinic Proc"},{"key":"ref39","first-page":"140","article-title":"Administration of aspirin-dipyridamole reduces proteinuria in diabetic nephropathy","volume":"4","author":"Hopper AH","year":"1989","journal-title":"Nephrol Dial Transplant","ISSN":"http:\/\/id.crossref.org\/issn\/0931-0509","issn-type":"print"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/003655902753679454","article-title":"A comparative randomized and placebo-controlled short-term trial of aspirin an dypiridamole for overt type-2 diabetic nephropathy","volume":"36","author":"Khajehdehi P","year":"2002","journal-title":"Scand J Urol Nephrol","ISSN":"http:\/\/id.crossref.org\/issn\/0036-5599","issn-type":"print"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.2337\/diacare.23.12.1742","article-title":"Lack of impact of low-dose acetylsalicylic acid on kidney function in type 1 diabetic patients with microalbuminuria","volume":"23","author":"Hansen HP","year":"2000","journal-title":"Diabetes Care","ISSN":"http:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/ndt\/18.3.539","article-title":"Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate","volume":"18","author":"Gaede P","year":"2003","journal-title":"Nephrol Dial Transplant","ISSN":"http:\/\/id.crossref.org\/issn\/0931-0509","issn-type":"print"},{"key":"ref43","first-page":"S874","article-title":"Efeito da aspirina em baixa dosagem sobre a excre\u00e7\u00e3o urin\u00e1ria de albumina e a taxa de filtra\u00e7\u00e3o glomerular em pacientes com diabete melito tipo 2 e microalbumin\u00faria","volume":"49","author":"Camargo EG","year":"2005","journal-title":"Arq Bras Endocrinol Metab"},{"key":"ref44","first-page":"215A","article-title":"Studies of left ventricular dysfunction (SOLVD): subgroup results","volume":"19","author":"Pitt B","year":"1992","journal-title":"J Am Coll Cardiol","ISSN":"http:\/\/id.crossref.org\/issn\/0735-1097","issn-type":"print"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0002-9343(00)00492-7","article-title":"Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease","volume":"109","author":"Peterson JG","year":"2000","journal-title":"Am J Med","ISSN":"http:\/\/id.crossref.org\/issn\/0002-9343","issn-type":"print"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0140-6736(02)11138-X","article-title":"Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review","volume":"360","author":"Teo KK","year":"2002","journal-title":"Lancet","ISSN":"http:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jacc.2005.05.060","article-title":"The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin.","volume":"46","author":"Fossum E","year":"2005","journal-title":"J Am Coll Cardiol","ISSN":"http:\/\/id.crossref.org\/issn\/0735-1097","issn-type":"print"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0161-6420(13)38010-5","article-title":"Effects of aspirin treatment on diabetic retinopathy: ETDRS report number 8","volume":"98","year":"1991","journal-title":"Ophthalmology","ISSN":"http:\/\/id.crossref.org\/issn\/0161-6420","issn-type":"print"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2337\/diacare.28.3.617","article-title":"Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: ETDRS report number 27","volume":"28","author":"Cusick M","year":"2005","journal-title":"Diabetes Care","ISSN":"http:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-142-5-200503010-00012","article-title":"Aspirin resistance and its clinical implications","volume":"142","author":"Sanderson S","year":"2005","journal-title":"Ann Intern Med","ISSN":"http:\/\/id.crossref.org\/issn\/0003-4819","issn-type":"print"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(06)68040-9","article-title":"Aspirin resistance","volume":"367","author":"Hankey GJ","year":"2006","journal-title":"Lancet","ISSN":"http:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.amjcard.2004.12.038","article-title":"Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction","volume":"95","author":"Schwartz KA","year":"2005","journal-title":"Am J Cardiol","ISSN":"http:\/\/id.crossref.org\/issn\/0002-9149","issn-type":"print"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0002-9149(01)01631-9","article-title":"Profile and prevalence of aspirin resistance in patients with cardiovascular disease","volume":"88","author":"Gum PA","year":"2001","journal-title":"Am J Cardiol","ISSN":"http:\/\/id.crossref.org\/issn\/0002-9149","issn-type":"print"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/bmj.326.7380.82","article-title":"Research pointers: platelet responsiveness to aspirin in patients with hyperlipidemia","volume":"326","author":"Friend M","year":"2003","journal-title":"BMJ","ISSN":"http:\/\/id.crossref.org\/issn\/0959-8138","issn-type":"print"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1161\/01.STR.25.2.275","article-title":"Failure of aspirin treatment after stroke","volume":"25","author":"Bornstein NM","year":"1994","journal-title":"Stroke","ISSN":"http:\/\/id.crossref.org\/issn\/0039-2499","issn-type":"print"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.thromres.2003.12.016","article-title":"Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)- its relation to metabolic control","volume":"113","author":"Watala C","year":"2004","journal-title":"Thromb Res","ISSN":"http:\/\/id.crossref.org\/issn\/0049-3848","issn-type":"print"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00109-004-0600-x","article-title":"Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin","volume":"83","author":"Watala C","year":"2005","journal-title":"J Mol Med","ISSN":"http:\/\/id.crossref.org\/issn\/0377-046X","issn-type":"print"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.2337\/diacare.26.7.2181","article-title":"The platelet in diabetes","volume":"26","author":"Colwell JA","year":"2003","journal-title":"Diabetes Care","ISSN":"http:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00592-005-0186-y","article-title":"Prevalence of aspirin resistance in patients with type 2 diabetes","volume":"42","author":"Fateh-Moghadam S","year":"2005","journal-title":"Acta Diabetol","ISSN":"http:\/\/id.crossref.org\/issn\/0940-5429","issn-type":"print"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.amjcard.2005.09.093","article-title":"Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus","volume":"97","author":"Mehta SS","year":"2006","journal-title":"Am J Cardiol","ISSN":"http:\/\/id.crossref.org\/issn\/0002-9149","issn-type":"print"}],"container-title":["Arquivos Brasileiros de Endocrinologia &amp; Metabologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abem\/v51n3\/a15v51n3.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,4]],"date-time":"2019-05-04T14:06:50Z","timestamp":1556978810000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-27302007000300015&lng=pt&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0004-27302007000300015"],"URL":"https:\/\/doi.org\/10.1590\/s0004-27302007000300015","relation":{},"ISSN":["0004-2730"],"issn-type":[{"value":"0004-2730","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}